Please login to the form below

Not currently logged in
Email:
Password:

US District Court blocks new patent rule

A district court judge has granted UK-based pharma giant GlaxoSmithKline's (GSK) motion for a preliminary injunction to prevent a new rule on patent claims and continuations from going into effect.

A district court judge has granted UK-based pharma giant GlaxoSmithKline's (GSK) motion for a preliminary injunction to prevent a new rule on patent claims and continuations from going into effect.

The US Patent and Trademark Office (PTO) announced the final rule in August 2007, which said that if a patent application contains more than five independent claims or more than 25 total claims, the applicant must provide an examination-support document to the PTO.

The new rule would have also modified how many continuing applications parties are allowed to file after submitting an initial application. Under the final rule, any third or subsequent continuation or continuation-in-part application, as well as any second or subsequent request for continued examination, must contain justification of why the new evidence was not submitted previously.

GSK sued the PTO on 9 October in the US. The District Court for the Eastern District of Virginia asked the court to enjoin the PTO from implementing the rule.

In its complaint, GSK argued that the PTO did not have the legal right to push through the rule as Congress had not finished passing the Patent Reform Act, which would give the PTO the ability to issue regulations relating to continuing applications. The House of Representatives has already passed its version of the legislation.

GSK also argued that the limit on the number of claims was unjust because companies are specifically permitted to file one or more claims under law. The company added that the examination-support document requirement was vague and burdensome.

The Pharmaceutical Research and Manufacturers of America (PhRMA) argued that the final rule would "impermissibly undercut long-held rights relating to the filing of patent applications that are important to pharmaceutical and biotechnology companies".

The US-based Biotechnology Industry Organisation (BIO) also submitted a motion, noting that "adverse effects of the final rules will nowhere be felt more strongly than in the biotechnology industry".

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics